GLOBAL MORPHO PHARMA

Global Morpho Pharma SAS is a French company created early 2018 that aims at developing, manufacturing, distributing and selling radionuclides and radiopharmaceuticals under Good Manufacturing Practice (GMP) quality for the benefit of the patients and the expanding nuclear medicine industry. Global Morpho Pharma intends to become one of the major suppliers of pharmaceutical grade doses of therapeutic radiolabeled compounds for the pharmaceutical industry and will primarily focus on non-carrier added Lutetium-177 and Actinium-225.